 Kent Westbrook
Concepts (80)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2015 | 1206 | 0.370 |
Why?
| | Lymph Nodes | 5 | 2015 | 252 | 0.340 |
Why?
| | Sentinel Lymph Node Biopsy | 5 | 2015 | 118 | 0.320 |
Why?
| | Carcinoma, Ductal, Breast | 3 | 2015 | 89 | 0.220 |
Why?
| | Ultrasonography, Mammary | 2 | 2015 | 61 | 0.200 |
Why?
| | Mastectomy, Segmental | 2 | 2015 | 92 | 0.190 |
Why?
| | Melanoma | 2 | 2016 | 280 | 0.170 |
Why?
| | Mastectomy | 3 | 2015 | 143 | 0.170 |
Why?
| | Neoplasm Staging | 5 | 2015 | 770 | 0.170 |
Why?
| | Nipples | 2 | 2011 | 33 | 0.150 |
Why?
| | Dermatologic Surgical Procedures | 2 | 2011 | 35 | 0.150 |
Why?
| | Skin Neoplasms | 2 | 2016 | 500 | 0.150 |
Why?
| | Biopsy, Needle | 2 | 2015 | 182 | 0.130 |
Why?
| | Axilla | 4 | 2015 | 92 | 0.130 |
Why?
| | S100 Proteins | 1 | 2016 | 34 | 0.130 |
Why?
| | Alopecia | 1 | 2016 | 38 | 0.120 |
Why?
| | Carcinoma, Lobular | 1 | 2015 | 32 | 0.120 |
Why?
| | Image-Guided Biopsy | 1 | 2015 | 34 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2011 | 643 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 334 | 0.110 |
Why?
| | Head and Neck Neoplasms | 1 | 2016 | 288 | 0.100 |
Why?
| | Aged | 12 | 2016 | 10109 | 0.100 |
Why?
| | Lymphography | 1 | 2011 | 8 | 0.090 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 46 | 0.090 |
Why?
| | Receptors, Estrogen | 2 | 2015 | 132 | 0.090 |
Why?
| | Frozen Sections | 1 | 2011 | 13 | 0.090 |
Why?
| | Mammaplasty | 1 | 2011 | 43 | 0.090 |
Why?
| | Middle Aged | 12 | 2016 | 13014 | 0.090 |
Why?
| | Lymphatic Metastasis | 4 | 2015 | 212 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1031 | 0.080 |
Why?
| | Adult | 10 | 2015 | 14139 | 0.070 |
Why?
| | Retrospective Studies | 7 | 2015 | 6578 | 0.070 |
Why?
| | Lymphatic Vessels | 1 | 2007 | 44 | 0.070 |
Why?
| | Receptor, erbB-2 | 1 | 2006 | 80 | 0.060 |
Why?
| | Carcinoma in Situ | 1 | 2006 | 72 | 0.060 |
Why?
| | Female | 12 | 2016 | 28105 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2015 | 2268 | 0.060 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2003 | 69 | 0.050 |
Why?
| | Laser Coagulation | 1 | 2003 | 27 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2015 | 3391 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2011 | 879 | 0.050 |
Why?
| | Prospective Studies | 3 | 2015 | 2428 | 0.040 |
Why?
| | Humans | 12 | 2016 | 52336 | 0.040 |
Why?
| | Prognosis | 3 | 2011 | 2094 | 0.040 |
Why?
| | Biopsy | 2 | 2016 | 604 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2015 | 5407 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 1543 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 37 | 0.030 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 2 | 2007 | 31 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 66 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2015 | 171 | 0.030 |
Why?
| | Lymph Node Excision | 2 | 2007 | 133 | 0.030 |
Why?
| | Radiopharmaceuticals | 2 | 2007 | 205 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2015 | 125 | 0.030 |
Why?
| | Carcinoma | 1 | 2015 | 137 | 0.030 |
Why?
| | Angiogenesis Inhibitors | 1 | 2015 | 183 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 236 | 0.030 |
Why?
| | X-Rays | 1 | 2011 | 55 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 1214 | 0.020 |
Why?
| | Cicatrix | 1 | 2011 | 42 | 0.020 |
Why?
| | Intraoperative Period | 1 | 2011 | 46 | 0.020 |
Why?
| | Young Adult | 2 | 2011 | 4319 | 0.020 |
Why?
| | Stereotaxic Techniques | 1 | 2010 | 40 | 0.020 |
Why?
| | Hematoma | 1 | 2010 | 65 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 278 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2011 | 713 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2010 | 138 | 0.020 |
Why?
| | Adolescent | 2 | 2011 | 6692 | 0.020 |
Why?
| | Coloring Agents | 1 | 2007 | 68 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 107 | 0.020 |
Why?
| | Lymphedema | 1 | 2007 | 48 | 0.020 |
Why?
| | Cohort Studies | 1 | 2011 | 1532 | 0.020 |
Why?
| | Surgical Flaps | 1 | 2005 | 110 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2006 | 636 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2002 | 51 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2002 | 158 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2003 | 247 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 985 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 943 | 0.010 |
Why?
| | Male | 1 | 2011 | 26696 | 0.010 |
Why?
|
|
Westbrook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|